Get the Stockscreener App
4.71
0.86%
0.04
Arbutus Biopharma Corp stock is traded at $4.71, with a volume of 1.57M.
It is up +0.86% in the last 24 hours and down -2.69% over the past month.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
See More
Previous Close:
$4.67
Open:
$4.68
24h Volume:
1.57M
Relative Volume:
1.44
Market Cap:
$905.85M
Revenue:
$12.99M
Net Income/Loss:
$-74.39M
P/E Ratio:
-10.70
EPS:
-0.44
Net Cash Flow:
$-78.92M
1W Performance:
+6.56%
1M Performance:
-2.69%
6M Performance:
+31.56%
1Y Performance:
+32.30%
1-Day Range:
$4.61
$4.81
1-Week Range:
$4.38
$4.81
52-Week Range:
$2.705
$5.10
Arbutus Biopharma Corp Stock (ABUS) Company Profile
Name
Arbutus Biopharma Corp
Sector
Industry
Phone
604-419-3200
Address
701 VETERANS CIRCLE, WARMINSTER, PA
Compare ABUS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABUS
Arbutus Biopharma Corp
|
4.71 | 898.15M | 12.99M | -74.39M | -78.92M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-02-22 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Initiated | Jefferies | Hold |
| Dec-17-20 | Initiated | H.C. Wainwright | Buy |
| Jul-27-20 | Resumed | JMP Securities | Mkt Outperform |
| Jul-24-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-19-20 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-06-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-20-20 | Initiated | Robert W. Baird | Outperform |
| Feb-05-20 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Oct-07-19 | Reiterated | B. Riley FBR | Buy |
| Oct-04-19 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-16-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Oct-15-18 | Upgrade | Wedbush | Underperform → Neutral |
| Oct-12-18 | Reiterated | Chardan Capital Markets | Buy |
| Jul-06-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Mar-19-18 | Resumed | Chardan Capital Markets | Buy |
| Mar-19-18 | Downgrade | Wedbush | Outperform → Neutral |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Apr-04-17 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-01-17 | Reiterated | Wedbush | Outperform |
| Dec-13-16 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Nov-30-16 | Upgrade | Chardan Capital Markets | Neutral → Buy |
View All
Arbutus Biopharma Corp Stock (ABUS) Latest News
BlackBarn Capital Partners LP Boosts Stock Position in Arbutus Biopharma Corporation $ABUS - MarketBeat
A Look at Arbutus Biopharma Corp (ABUS) Shares in the Recent Past Indicates Growth - setenews.com
Arbutus Biopharma Corp Discusses Ongoing Patent Litigation - TradingView — Track All Markets
Arbutus Biopharma Corporation $ABUS Shares Purchased by Two Seas Capital LP - MarketBeat
The time has not yet come to remove your chips from the table: Arbutus Biopharma Corp (ABUS) - setenews.com
Why global investors buy Arbutus Biopharma Corporation (I9DN) stockWeekly Trend Summary & Community Supported Trade Ideas - Newser
Can Arbutus Biopharma Corporation (I9DN) stock hold up in economic slowdown2025 Year in Review & Real-Time Stock Entry Alerts - Newser
Is Arbutus Biopharma Corporation (I9DN) stock a buy for dividend portfoliosPortfolio Value Report & Fast Moving Stock Trade Plans - Newser
Arbutus Biopharma (ABUS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
How Arbutus Biopharma Corporation (I9DN) stock trades after earningsJuly 2025 Short Interest & Capital Efficiency Focused Strategies - Newser
Why Arbutus Biopharma Corporation (I9DN) stock could outperform next yearJuly 2025 Short Interest & Safe Capital Allocation Plans - Newser
There is no way Arbutus Biopharma Corp (ABUS) can keep these numbers up - setenews.com
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above 200 Day Moving AverageHere's What Happened - MarketBeat
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above 200 Day Moving Average – Here’s What Happened - Defense World
How Arbutus Biopharma Corporation (I9DN) stock reacts to new regulationsEarnings Risk Summary & Weekly Setup with High ROI Potential - newser.com
A look into Arbutus Biopharma Corp (ABUS)’s deeper side - Setenews
Why Arbutus Biopharma Corporation stock is trending among retail tradersJuly 2025 Volume & Daily Growth Stock Tips - newser.com
Arbutus Reports Major Advances in HBV Candidate as Litigation Against Moderna, Pfizer Builds Toward Trial - MyChesCo
Arbutus Biopharma Corporation stock trend outlook and recovery pathQuarterly Market Summary & Daily Price Action Insights - newser.com
How Arbutus Biopharma Corporation (I9DN) stock compares with market leadersWeekly Trade Analysis & Growth Oriented Trading Recommendations - newser.com
How Arbutus Biopharma Corporation stock compares to growth peersMarket Risk Analysis & Fast Moving Trade Plans - newser.com
Arbutus Biopharma’s (ABUS) Buy Rating Reiterated at Chardan Capital - Defense World
Quantitative breakdown of Arbutus Biopharma Corporation recent move2025 Big Picture & Reliable Intraday Trade Plans - newser.com
Arbutus Biopharma (NASDAQ:ABUS) Given Buy Rating at Chardan Capital - MarketBeat
What indicators show strength in Arbutus Biopharma Corporation2025 Investor Takeaways & Low Volatility Stock Recommendations - newser.com
What analysts say about Arbutus Biopharma Corporation I9DN stockBull Market Opportunities & Follow Top Performers in the Community - earlytimes.in
Arbutus Biopharma (ABUS) Receives Steady Buy Rating from Chardan Capital | ABUS Stock News - GuruFocus
Arbutus Biopharma Faces Losses And Legal Battles This Quarter - Finimize
Arbutus: Q3 Earnings Snapshot - New Haven Register
Arbutus Biopharma earnings missed, revenue fell short of estimates By Investing.com - Investing.com South Africa
Arbutus Biopharma shares rise as imdusiran data shows promising results By Investing.com - Investing.com Canada
Arbutus Biopharma shares rise as imdusiran data shows promising results - Investing.com
Arbutus Biopharma earnings missed, revenue fell short of estimates - Investing.com
Arbutus (ABUS) Reports Q3 Results, Highlights Promising Imdusira - GuruFocus
Nothing is Better Than Arbutus Biopharma Corp (ABUS) stock at the moment - Setenews
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Arbutus Biopharma Corp SEC 10-Q Report - TradingView
Arbutus Biopharma Corp Stock (ABUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):